In a blog post in The BMJ Opinion, Kanchan Mukherjee, a medical doctor and professor at the Tata Institute of Social Sciences in Mumbai, discusses the potential benefits and challenges of a wider government rollout of bedaquiline to treat multidrug-resistant TB in India.
